Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years
Phase of Trial: Phase III
Latest Information Update: 12 Sep 2018
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 01 Aug 2018 Last checked against the European Clinical Trials Database record.
- 09 Jul 2018 Planned number of patients changed from 176 to 200.
- 09 Jul 2018 Planned End Date changed from 28 Feb 2019 to 28 Feb 2020.